Drugmakers Appeal to Supreme Court to Reinstate Mail-Order Access to Mifepristone

Danco Laboratories and GenBioPro have filed emergency appeals with the U.S. Supreme Court, seeking to overturn a ruling by the 5th U.S. Circuit Court of Appeals that mandates in-person distribution of the abortion pill mifepristone. The appellate court's decision, issued on May 1, 2026, prohibits the mailing of mifepristone prescriptions, a method that had been increasingly utilized to provide access to the medication.

Danco Laboratories argued that the appellate ruling "injects immediate confusion and upheaval into highly time-sensitive medical decisions." GenBioPro, which produces a generic version of mifepristone, also requested the Supreme Court's intervention to maintain mail-order access to the drug.

The 5th Circuit's ruling aligns with efforts by abortion opponents to limit the distribution of abortion pills prescribed online, viewing such practices as circumventing state bans on the procedure. The decision requires that mifepristone be dispensed only in person at clinics, overriding previous regulations set by the Food and Drug Administration (FDA).

Mifepristone has been FDA-approved since 2000 and is commonly used alongside misoprostol for early-stage abortions. The appellate court's decision challenges the FDA's longstanding approval and regulation of the medication, which has been increasingly accessed via telehealth, especially in states with abortion bans.

The Supreme Court's response to these emergency appeals will have significant implications for abortion access nationwide, particularly concerning the availability of medication abortions through telehealth and mail delivery services.